Anticardiolipin antibody in vascular parkinsonism
Identifieur interne : 001282 ( Istex/Corpus ); précédent : 001281; suivant : 001283Anticardiolipin antibody in vascular parkinsonism
Auteurs : Zhigao Huang ; Michael Jacewicz ; Ronald F. PfeifferSource :
- Movement Disorders [ 0885-3185 ] ; 2002-09.
English descriptors
Abstract
Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini‐Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA− groups. Since the presence of ACLA in individuals with stroke is usually treated by full‐scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10219
Links to Exploration step
ISTEX:6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anticardiolipin antibody in vascular parkinsonism</title><author><name sortKey="Huang, Zhigao" sort="Huang, Zhigao" uniqKey="Huang Z" first="Zhigao" last="Huang">Zhigao Huang</name><affiliation><mods:affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</mods:affiliation></affiliation></author><author><name sortKey="Jacewicz, Michael" sort="Jacewicz, Michael" uniqKey="Jacewicz M" first="Michael" last="Jacewicz">Michael Jacewicz</name><affiliation><mods:affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</mods:affiliation></affiliation></author><author><name sortKey="Pfeiffer, Ronald F" sort="Pfeiffer, Ronald F" uniqKey="Pfeiffer R" first="Ronald F." last="Pfeiffer">Ronald F. Pfeiffer</name><affiliation><mods:affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10219</idno><idno type="url">https://api.istex.fr/document/6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001282</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anticardiolipin antibody in vascular parkinsonism</title><author><name sortKey="Huang, Zhigao" sort="Huang, Zhigao" uniqKey="Huang Z" first="Zhigao" last="Huang">Zhigao Huang</name><affiliation><mods:affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</mods:affiliation></affiliation></author><author><name sortKey="Jacewicz, Michael" sort="Jacewicz, Michael" uniqKey="Jacewicz M" first="Michael" last="Jacewicz">Michael Jacewicz</name><affiliation><mods:affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</mods:affiliation></affiliation></author><author><name sortKey="Pfeiffer, Ronald F" sort="Pfeiffer, Ronald F" uniqKey="Pfeiffer R" first="Ronald F." last="Pfeiffer">Ronald F. Pfeiffer</name><affiliation><mods:affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="992">992</biblScope><biblScope unit="page" to="997">997</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99</idno><idno type="DOI">10.1002/mds.10219</idno><idno type="ArticleID">MDS10219</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>anticardiolipin antibody</term><term>gait disorder</term><term>vascular parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini‐Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA− groups. Since the presence of ACLA in individuals with stroke is usually treated by full‐scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive. © 2002 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Zhigao Huang MD</name><affiliations><json:string>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</json:string></affiliations></json:item><json:item><name>Michael Jacewicz MD</name><affiliations><json:string>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</json:string></affiliations></json:item><json:item><name>Ronald F. Pfeiffer MD</name><affiliations><json:string>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>vascular parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anticardiolipin antibody</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>gait disorder</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini‐Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA− groups. Since the presence of ACLA in individuals with stroke is usually treated by full‐scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive. © 2002 Movement Disorder Society</abstract><qualityIndicators><score>6.387</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1262</abstractCharCount><pdfWordCount>3715</pdfWordCount><pdfCharCount>24085</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>181</abstractWordCount></qualityIndicators><title>Anticardiolipin antibody in vascular parkinsonism</title><genre><json:string>Serial article</json:string></genre><host><volume>17</volume><pages><total>6</total><last>997</last><first>992</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/mds.10219</json:string></doi><id>6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Anticardiolipin antibody in vascular parkinsonism</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Anticardiolipin antibody in vascular parkinsonism</title><author><persName><forename type="first">Zhigao</forename><surname>Huang</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</affiliation></author><author><persName><forename type="first">Michael</forename><surname>Jacewicz</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</affiliation></author><author><persName><forename type="first">Ronald F.</forename><surname>Pfeiffer</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: University of Tennessee Health Science Center, Department of Neurology, 855 Monroe Avenue, 415 Link, Memphis, TN 38163</p></note><affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09"></date><biblScope unit="vol">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="992">992</biblScope><biblScope unit="page" to="997">997</biblScope></imprint></monogr><idno type="istex">6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99</idno><idno type="DOI">10.1002/mds.10219</idno><idno type="ArticleID">MDS10219</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini‐Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA− groups. Since the presence of ACLA in individuals with stroke is usually treated by full‐scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive. © 2002 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>vascular parkinsonism</term></item><item><term>anticardiolipin antibody</term></item><item><term>gait disorder</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-08-16">Received</change><change when="2002-02-20">Registration</change><change when="2002-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v17:5</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2002-09">September/October 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="150" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10219</doi><idGroup><id type="unit" value="MDS10219"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Article</title></titleGroup><copyright ownership="thirdParty">Copyright © 2002 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2001-08-16"></event><event type="manuscriptRevised" date="2002-02-18"></event><event type="manuscriptAccepted" date="2002-02-20"></event><event type="publishedOnlineEarlyUnpaginated" date="2002-04-15"></event><event type="firstOnline" date="2002-04-15"></event><event type="publishedOnlineFinalForm" date="2002-09-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">992</numbering><numbering type="pageLast">997</numbering></numberingGroup><correspondenceTo>University of Tennessee Health Science Center, Department of Neurology, 855 Monroe Avenue, 415 Link, Memphis, TN 38163</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10219.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="46"></count><count type="wordTotal" number="3583"></count></countGroup><titleGroup><title type="main" xml:lang="en">Anticardiolipin antibody in vascular parkinsonism</title><title type="short" xml:lang="en">ACLA In Vascular Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Zhigao</givenNames><familyName>Huang</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michael</givenNames><familyName>Jacewicz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Ronald F.</givenNames><familyName>Pfeiffer</familyName><degrees>MD</degrees></personName><contactDetails><email>rpfeiffer@utmem.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">vascular parkinsonism</keyword><keyword xml:id="kwd2">anticardiolipin antibody</keyword><keyword xml:id="kwd3">gait disorder</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini‐Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA− groups. Since the presence of ACLA in individuals with stroke is usually treated by full‐scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive. © 2002 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Anticardiolipin antibody in vascular parkinsonism</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ACLA In Vascular Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Anticardiolipin antibody in vascular parkinsonism</title></titleInfo><name type="personal"><namePart type="given">Zhigao</namePart><namePart type="family">Huang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Jacewicz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ronald F.</namePart><namePart type="family">Pfeiffer</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA</affiliation><description>Correspondence: University of Tennessee Health Science Center, Department of Neurology, 855 Monroe Avenue, 415 Link, Memphis, TN 38163</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2002-09</dateIssued><dateCaptured encoding="w3cdtf">2001-08-16</dateCaptured><dateValid encoding="w3cdtf">2002-02-20</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">3</extent><extent unit="references">46</extent><extent unit="words">3583</extent></physicalDescription><abstract lang="en">Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini‐Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA− groups. Since the presence of ACLA in individuals with stroke is usually treated by full‐scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive. © 2002 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>vascular parkinsonism</topic><topic>anticardiolipin antibody</topic><topic>gait disorder</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>992</start><end>997</end><total>6</total></extent></part></relatedItem><identifier type="istex">6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99</identifier><identifier type="DOI">10.1002/mds.10219</identifier><identifier type="ArticleID">MDS10219</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 Movement Disorders Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001282 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001282 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6858F2E6B9C2BFBE0FC2634FAB1BAFD064989F99
|texte= Anticardiolipin antibody in vascular parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |